secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-10-09T11:59:32+00:00
Accession:  0001193125-26-418538
Event type: leadership
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.02, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Quince Therapeutics renamed IRulya; Roberts named CEO, Militello CFO, Fandrick COO effective Oct 8, 2026
--------------------------------------------------------------------------------

- Brigette Roberts, M.D. became CEO effective Oct 8, 2026 with $600,000 base salary and 50% target bonus; John Militello, CPA became CFO and Keith Fandrick, Ph.D. became COO.
- Dirk Thye resigned as CEO, CMO and director and Brendan Hannah resigned as COO, CBO and CCO; June Bray, David Lamond, Christopher Senner and Thye also left the Board with no disagreements.
- Name change to IRulya Therapeutics Inc. is effective 4:01 p.m. ET Oct 9, 2026; common stock moves to Nasdaq Capital Market under IRLA effective Oct 12, 2026, with CUSIP unchanged.
- Cash balance was $116 million as of June 30, 2026 and is expected to fund operations through end of 2028, supporting Phase 2 data readouts for LAM-001 in BOS, PH-ILD and SAPH.
- Board added Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise effective Oct 8, 2026; Patterson chairs Audit/Compensation, Valentine chairs Governance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/0001193125-26-418538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/d172110d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-418538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer